This site is intended for health professionals only

NICE approves Yescarta for relapsed/remitted lymphomas

Yescarta has been approved by NICE for use adults with two forms of relapsed/refractory lymphomas after two or more lines of prior therapy

The CAR-T cell therapy, Yescarta (axicabtagene ciloleucel), has been approved by for use in the UK by NICE, in adult patients who have either relapsed or refractory diffuse large-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), following the use of two or more lines of systemic treatment.

chimeric antigen receptor T-cell (CAR-T) therapy is a form of personalised immunotherapy that utilises the patient’s own immune which are modified to destroy cancer cells. DLBCL is a non-Hodgkin lymphoma (NHL) and while in the UK alone, there are around 14,200 annual cases of the NHL DLBCL accounts for around 40% of all NHL cases or roughly 5,500 patients. In contrast, PMBCL is much rarer, accounting for 2 to 4 % of all NHL cases (around 330 cases in the UK).

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

Following initial chemotherapy, up to 45% of those with DLBCL require a second-line treatment such as a stem cell transplant and of these, around 50% ultimately relapse. Moreover, it has been estimated that only 60% of patients will survive for longer than 5 years after their diagnosis.

The decision to approve yescarta was based information from the cancer drugs fund, which showed that a total of 318 patients received treatment and showed a median overall survival of those given axicabtagene ciloleucel was 28.5 months and 45% of people were alive after three years.

The full guidance issued by NICE is expected to the published at the end of February 2023.

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine